Mirae Asset Global Investments Co. Ltd. Buys New Position in iShares Biotechnology ETF $IBB

Posted by Jeff Wilder on Nov 6th, 2026

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,691 shares of the financial services provider’s stock, valued at approximately $6,040,000. Mirae Asset Global Investments Co. Ltd. owned approximately 0.06% of iShares Biotechnology ETF at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Kaydan Wealth Management Inc. lifted its stake in iShares Biotechnology ETF by 3.9% during the 3rd quarter. Kaydan Wealth Management Inc. now owns 1,363 shares of the financial services provider’s stock valued at $287,000 after acquiring an additional 51 shares in the last quarter. Carter Financial Group INC. grew its stake in shares of iShares Biotechnology ETF by 2.2% in the 2nd quarter. Carter Financial Group INC. now owns 2,423 shares of the financial services provider’s stock worth $461,000 after acquiring an additional 53 shares in the last quarter. Parallel Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 8.8% in the 1st quarter. Parallel Advisors LLC now owns 744 shares of the financial services provider’s stock worth $126,000 after acquiring an additional 60 shares in the last quarter. Apollon Wealth Management LLC raised its holdings in shares of iShares Biotechnology ETF by 0.7% in the third quarter. Apollon Wealth Management LLC now owns 8,178 shares of the financial services provider’s stock valued at $1,722,000 after purchasing an additional 60 shares during the last quarter. Finally, Global Assets Advisory LLC raised its holdings in shares of iShares Biotechnology ETF by 3.1% in the third quarter. Global Assets Advisory LLC now owns 2,082 shares of the financial services provider’s stock valued at $432,000 after purchasing an additional 62 shares during the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 5.0%

Shares of IBB stock opened at $210.18 on Friday. The firm has a 50-day moving average of $208.49 and a 200-day moving average of $185.69. iShares Biotechnology ETF has a one year low of $154.98 and a one year high of $222.29.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Tuesday, September 15th were given a $0.0112 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date of this dividend was Tuesday, September 15th. This is a negative change from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.